Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease
Objective: To investigate the potential of transcranial static magnetic field stimulation (tSMS) as a non-pharmacological, non-invasive, home-based treatment to manage levodopa-induced dyskinesias (LIDs) in Parkinson’s…Bitopertin, a GlyT1 inhibitor, attenuates the development of dyskinesia in the 6-OHDA-lesioned rat
Objective: To evaluate the effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin at preventing dyskinesia development in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s…Relationship between lesion topography and incidence of dyskinesias following focused ultrasound subthalamotomy.
Objective: To describe the relation between the topography of subthalamotomy by focused ultrasound (FUS) for the treatment of Parkinson’s disease (PD) (1), and the risk…Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis
Objective: Compare real-world clinical outcomes of Parkinson’s disease (PD) patients with moderate/severe motor fluctuations and/or dyskinesia treated with oral medications compared to device-aided therapies. Background:…Validation of the PD Home Diary for Assessment of Motor Fluctuations in Advanced Parkinson’s Disease
Objective: To determine the validity of the Parkinson’s disease (PD) home diary for quantification of motor states in patients with advanced PD and motor fluctuations.…Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias
Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…Movement disorders in pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis
Objective: Our aim was to investigate clinical characteristics and evolution of movement disorders (MD) in pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Background: Movement disorders account for…Determination of glycine transporter 1 levels with [3H]-NFPS binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia
Objective: To determine the distribution of the glycine transporter 1 (GlyT1) in brain areas implicated in parkinsonism and L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia in the 6-hydroxydopamine…Prevalence of Movement Disorders After Acute Stroke: a Large Prospective Cohort Stroke Study
Objective: To ascertain the prevalence of acute post-stroke movement disorders (PSMD) in a prospective cohort of acute stroke patients. Background: Post-stroke movement disorders can occur…Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 40
- Next Page »